Sophiris Bio Inc (NASDAQ:SPHS), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced financial results for the three and …
Shares of Sophiris Bio Inc (NASDAQ:SPHS) surged by more than 90% today as a result of positive results from its mid-stage trial. The company announced …
Sophiris Bio Inc (NASDAQ:SPHS) shareholders celebrate over 110% gain in the stock this morning, after the drug maker announced positive results from its Phase IIa open-label, …
Healthcare analysts are weighing in on biotech stocks Portola Pharmaceuticals Inc (NASDAQ:PTLA) and Sophiris Bio Inc (NASDAQ:SPHS), as shares of both companies fell sharply …
By Terry Chrisomalis Anavex Life Sciences Corp On November 9, 2015 Anavex Life Sciences Corp. (NASDAQ:AVXL) reported positive phase 2a results for the …
Maxim Group’s healthcare analyst Jason Kolbert weighed in today with research reports on the Canadian urology company Sophiris Bio Inc (NASDAQ:SPHS), Israeli stem cell company Pluristem Therapeutics Inc. (NASDAQ:PSTI), …
In a research report released Tuesday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Sophiris Bio Inc (NASDAQ:SPHS), but reduced his price …
Maxim Group analyst Jason Kolbert maintained a Buy rating on Sophiris Bio Inc (NASDAQ:SPHS) with a price target of $10, which represents a …
